Results released today from the Pre-Exposure Prophylaxis Initiative (iPrEx) study confirmed that daily oral use of a combination antiretroviral (ARV), Truvada, reduced the risk of HIV infection by 44 percent among men who have sex with men. This historic iPrEx trial provides the first proof of concept that oral PrEP of an ARV can prevent [...]

Read the rest of this entry »